CoChat
Sign Up
Cited by 40Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and TreatmentCancer, Lipids, and Metabolism

Drug Repurposing, an Attractive Strategy in Pancreatic Cancer Treatment: Preclinical and Clinical Updates

Open access
De Lellis, Laura, Veschi, Serena, Tinari, Nicola, Mokini, Zhirajr, Carradori, Simone, Brocco, Davide, Florio, Rosalba, Grassadonia, Antonino +1 more·2021·Cancers
DOI 10.3390/cancers13163946PMC PMC8394389
Open this paper in CoChat — free accountOpen PDF

Abstract

Pancreatic cancer (PC) is one of the deadliest malignancies worldwide, since patients rarely display symptoms until an advanced and unresectable stage of the disease. Current chemotherapy options are unsatisfactory and there is an urgent need for more effective and less toxic drugs to improve the dismal PC therapy. Repurposing of non-oncology drugs in PC treatment represents a very promising therapeutic option and different compounds are currently being considered as candidates for repurposing in the treatment of this tumor. In this review, we provide an update on some of the most promising FDA-approved, non-oncology, repurposed drug candidates that show prominent clinical and preclinical data in pancreatic cancer. We also focus on proposed mechanisms of action and known molecular targets that they modulate in PC. Furthermore, we provide an explorative bioinformatic analysis, which suggests that some of the PC repurposed drug candidates have additional, unexplored, oncology-relevant targets. Finally, we discuss recent developments regarding the immunomodulatory role displayed by some of these drugs, which may expand their potential application in synergy with approved anticancer immunomodulatory agents that are mostly ineffective as single agents in PC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers13163946

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Candidate repurposed drugs have well-documented pharmacokinetic, pharmacodynamic, dosing and toxicity profiles that accelerate their clinical development.

    “The rationale for this is that the candidate drugs have well‐documented and established pharmacokinetic, pharmacodynamic, dosing and toxicity profiles that accelerate their clinical development [6].”

    From Pyrvinium Pamoate Alone and With Gemcitabine Exhibits Anti‐Pancreatic Cancer Activity in <scp>2D</scp> and <scp>3D</scp> Cell Culture Models (2024) · cites this paper as [6]

    The Introduction states that repurposing candidates have established pharmacokinetic, pharmacodynamic, dosing and toxicity profiles. It says these profiles *may* accelerate clinical development, whereas the citing sentence presents acceleration as certain. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 207

  1. [1]Rahib L. Smith B.D. Aizenberg R. Rosenzweig A.B. Fleshman J.M. Matrisian L.M. Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States Cancer Res. 2014 74 2913 2921 10.1158/0008-5472.CAN-14-0155 24840647 · DOI · Paper page
  2. [2]Adamska A. Domenichini A. Falasca M. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies Int. J. Mol. Sci. 2017 18 1338 10.3390/ijms18071338 28640192 PMC5535831 · DOI
  3. [3]Franck C. Müller C. Rosania R. Croner R.S. Pech M. Venerito M. Advanced Pancreatic Ductal Adenocarcinoma: Moving Forward Cancers 2020 12 1955 10.3390/cancers12071955 PMC7409054 32708493 · DOI
  4. [5]Marabelle A. Le D.T. Ascierto P.A. Di Giacomo A.M. De Jesus-Acosta A. Delord J.-P. Geva R. Gottfried M. Penel N. Hansen A.R. Efficacy of Pembrolizumab in Patients with Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results from the Phase II KEYNOTE-158 Study J. Clin. Oncol. 2020 38 1 10 10.1200/JCO.19.02105 31682550 PMC8184060 · DOI
  5. [6]Gillen S. Schuster T. Büschenfelde C.M.Z. Friess H. Kleeff J. Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages PLoS Med. 2010 7 e1000267 10.1371/journal.pmed.1000267 20422030 PMC2857873 · DOI
  6. [7]A decade in drug discovery Nat. Rev. Drug Discov. 2012 11 3 10.1038/nrd3648 22329019 · DOI
  7. [8]Scannell J.W. Blanckley A. Boldon H. Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency Nat. Rev. Drug Discov. 2012 11 191 200 10.1038/nrd3681 22378269 · DOI · Paper page
  8. [9]Maeda H. Khatami M. Analyses of repeated failures in cancer therapy for solid tumors: Poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs Clin. Transl. Med. 2018 7 11 10.1186/s40169-018-0185-6 29541939 PMC5852245 · DOI · Paper page
  9. [10]Zhang Z. Zhou L. Xie N. Nice E.C. Zhang T. Cui Y. Huang C. Overcoming cancer therapeutic bottleneck by drug repurposing Signal Transduct. Target. Ther. 2020 5 113 10.1038/s41392-020-00213-8 32616710 PMC7331117 · DOI
  10. [11]Pushpakom S. Iorio F. Eyers P.A. Escott K.J. Hopper S. Wells A. Doig A. Guilliams T. Latimer J. McNamee C. Drug repurposing: Progress, challenges and recommendations Nat. Rev. Drug Discov. 2019 18 41 58 10.1038/nrd.2018.168 30310233 · DOI · Paper page
  11. [13]Nosengo N. Can you teach old drugs new tricks? Nature 2016 534 314 316 10.1038/534314a 27306171 · DOI
  12. [14]Shim J.S. Liu J.O. Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs Int. J. Biol. Sci. 2014 10 654 663 10.7150/ijbs.9224 25013375 PMC4081601 · DOI · Paper page
  13. [15]Palumbo A. Bringhen S. Caravita T. Merla E. Capparella V. Callea V. Cangialosi C. Grasso M. Rossini F. Galli M. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial Lancet 2006 367 825 831 10.1016/S0140-6736(06)68338-4 16530576 · DOI
  14. [16]Léauté-Labrèze C. de la Roque E.D. Hubiche T. Boralevi F. Thambo J.-B. Taïeb A. Propranolol for Severe Hemangiomas of Infancy N. Engl. J. Med. 2008 358 2649 2651 10.1056/NEJMc0708819 18550886 · DOI
  15. [17]Krowchuk D.P. Frieden I.J. Mancini A.J. Darrow D.H. Blei F. Greene A.K. Annam A. Baker C.N. Frommelt P.C. Hodak A. Clinical Practice Guideline for the Management of Infantile Hemangiomas Pediatrics 2019 143 e20183475 10.1542/peds.2018-3475 30584062 · DOI
  16. [18]Aggarwal S. Verma S.S. Aggarwal S. Gupta S.C. Drug repurposing for breast cancer therapy: Old weapon for new battle Semin. Cancer Biol. 2021 68 8 20 10.1016/j.semcancer.2019.09.012 31550502 PMC7128772 · DOI
  17. [20]Perez M.V.R. Roife D. Dai B. Pratt M. Dobrowolski R. Kang Y. Li X. Augustine J.J. Zielinski R. Priebe W. Antineoplastic effects of auranofin in human pancreatic adenocarcinoma preclinical models Surg. Open Sci. 2019 1 56 63 10.1016/j.sopen.2019.05.004 33981979 PMC8083010 · DOI
  18. [21]Onodera T. Momose I. Adachi H. Yamazaki Y. Sawa R. Ohba S. Kawada M. Human pancreatic cancer cells under nutrient deprivation are vulnerable to redox system inhibition J. Biol. Chem. 2020 295 16678 16690 10.1074/jbc.RA120.013893 32978257 PMC7864064 · DOI
  19. [22]Kshattry S. Saha A. Gries P. Tiziani S. Stone E. Georgiou G. DiGiovanni J. Enzyme-mediated depletion of l-cyst(e)ine synergizes with thioredoxin reductase inhibition for suppression of pancreatic tumor growth NPJ Precis. Oncol. 2019 3 16 10.1038/s41698-019-0088-z 31231686 PMC6546752 · DOI
  20. [23]Jandaghi P. Najafabadi H.S. Bauer A.S. Papadakis A.I. Fassan M. Hall A. Monast A. von Knebel Doeberitz M. Neoptolemos J.P. Costello E. Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice Gastroenterology 2016 151 1218 1231 10.1053/j.gastro.2016.08.040 27578530 · DOI
  21. [24]Kim S.H. Lee H.Y. Yi H. Ahn Y.M. Kim Y.S. Haloperidol induces demethylation and expression of the dual specificity phosphatase 6 gene in MIA PaCa-2 human pancreatic cancer cells Life Sci. 2012 91 1317 1322 10.1016/j.lfs.2012.10.002 23063941 · DOI
  22. [25]Ranjan A. Srivastava S.K. Penfluridol suppresses pancreatic tumor growth by autophagy-mediated apoptosis Sci. Rep. 2016 6 26165 10.1038/srep26165 27189859 PMC4870635 · DOI
  23. [26]Ranjan A. German N. Mikelis C. Srivenugopal K. Srivastava S.K. Penfluridol induces endoplasmic reticulum stress leading to autophagy in pancreatic cancer Tumor Biol. 2017 39 101042831770551 10.1177/1010428317705517 28618969 · DOI
  24. [28]Dandawate P. Kaushik G. Ghosh C. Standing D. Sayed A.A.A. Choudhury S. Subramaniam D. Manzardo A. Banerjee T. Santra S. Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice Gastroenterology 2020 158 1433 1449.e27 10.1053/j.gastro.2019.11.279 31786131 PMC7103550 · DOI
  25. [29]Florio R. Veschi S. di Giacomo V. Pagotto S. Carradori S. Verginelli F. Cirilli R. Casulli A. Grassadonia A. Tinari N. The Benzimidazole-Based Anthelmintic Parbendazole: A Repurposed Drug Candidate That Synergizes with Gemcitabine in Pancreatic Cancer Cancers 2019 11 2042 10.3390/cancers11122042 31861153 PMC6966614 · DOI
  26. [30]Han J. Liu L. Yue X. Chang J. Shi W. Hua Y. A binuclear complex constituted by diethyldithiocarbamate and copper (I) functions as a proteasome activity inhibitor in pancreatic cancer cultures and xenografts Toxicol. Appl. Pharmacol. 2013 273 477 483 10.1016/j.taap.2013.09.009 24060341 · DOI
  27. [31]Cong J. Wang Y. Zhang X. Zhang N. Liu L. Soukup K. Michelakos T. Hong T. DeLeo A. Cai L. A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram Cancer Lett. 2017 409 9 19 10.1016/j.canlet.2017.08.028 28864067 · DOI
  28. [32]Dinnen R.D. Mao Y. Qiu W. Cassai N. Slavkovich V.N. Nichols G. Su G.H. Brandt-Rauf P. Fine R.L. Redirecting Apoptosis to Aponecrosis Induces Selective Cytotoxicity to Pancreatic Cancer Cells through Increased ROS, Decline in ATP Levels, and VDAC Mol. Cancer Ther. 2013 12 2792 2803 10.1158/1535-7163.MCT-13-0234 24126434 PMC4318573 · DOI
  29. [33]Zhang X. Hu P. Ding S.-Y. Sun T. Liu L. Han S. DeLeo A.B. Sadagopan A. Guo W. Wang X. Induction of autophagy-dependent apoptosis in cancer cells through activation of ER stress: An uncovered anti-cancer mechanism by anti-alcoholism drug disulfiram Am. J. Cancer Res. 2019 9 1266 1281 31285958 PMC6610050
  30. [34]Son K. Fujioka S. Iida T. Furukawa K. Fujita T. Yamada H. Chiao P.J. Yanaga K. Doxycycline induces apoptosis in PANC-1 pancreatic cancer cells Anticancer Res. 2009 29 3995 4003 19846942
  31. [35]Mouratidis P.X.E. Colston K.W. Dalgleish A.G. Doxycycline induces caspase-dependent apoptosis in human pancreatic cancer cells Int. J. Cancer 2007 120 743 752 10.1002/ijc.22303 17131308 · DOI
  32. [36]Lamb R. Ozsvari B. Lisanti C.L. Tanowitz H.B. Howell A. Martinez-Outschoorn U.E. Sotgia F. Lisanti M.P. Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease Oncotarget 2015 6 4569 4584 10.18632/oncotarget.3174 25625193 PMC4467100 · DOI
  33. [37]Dijk S.N. Protasoni M. Elpidorou M. Kroon A.M. Taanman J.-W. Mitochondria as target to inhibit proliferation and induce apoptosis of cancer cells: The effects of doxycycline and gemcitabine Sci. Rep. 2020 10 4363 10.1038/s41598-020-61381-9 32152409 PMC7063048 · DOI
  34. [38]Liu H. Tao H. Wang H. Yang Y. Yang R. Dai X. Ding X. Wu H. Chen S. Sun T. Doxycycline Inhibits Cancer Stem Cell-Like Properties via PAR1/FAK/PI3K/AKT Pathway in Pancreatic Cancer Front. Oncol. 2021 10 619317 10.3389/fonc.2020.619317 33643917 PMC7905084 · DOI
  35. [39]Hecht M. Erber S. Harrer T. Klinker H. Roth T. Parsch H. Fiebig N. Fietkau R. Distel L.V. Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells PLoS ONE 2015 10 e0130277 10.1371/journal.pone.0130277 26086472 PMC4473268 · DOI
  36. [40]Hecht M. Harrer T. Körber V. Sarpong E. Moser F. Fiebig N. Schwegler M. Stürzl M. Fietkau R. Distel L. Cytotoxic effect of Efavirenz in BxPC-3 pancreatic cancer cells is based on oxidative stress and is synergistic with ionizing radiation Oncol. Lett. 2017 15 1728 1736 10.3892/ol.2017.7523 29434868 PMC5776903 · DOI
  37. [41]Kimple R.J. Vaseva A.V. Cox A.D. Baerman K.M. Calvo B.F. Tepper J.E. Shields J.M. Sartor C.I. Radiosensitization of Epidermal Growth Factor Receptor/HER2-Positive Pancreatic Cancer Is Mediated by Inhibition of Akt Independent of Ras Mutational Status Clin. Cancer Res. 2010 16 912 923 10.1158/1078-0432.CCR-09-1324 20103665 PMC2818631 · DOI
  38. [42]Veschi S. De Lellis L. Florio R. Lanuti P. Massucci A. Tinari N. De Tursi M. di Sebastiano P. Marchisio M. Natoli C. Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells J. Exp. Clin. Cancer Res. 2018 37 236 10.1186/s13046-018-0904-2 30241558 PMC6151049 · DOI
  39. [43]Batchu R. Gruzdyn O. Bryant C. Qazi A. Kumar S. Chamala S. Kung S. Sanka R. Puttagunta U. Weaver D. Ritonavir-Mediated Induction of Apoptosis in Pancreatic Cancer Occurs via the RB/E2F-1 and AKT Pathways Pharmaceuticals 2014 7 46 57 10.3390/ph7010046 24451403 PMC3915194 · DOI
  40. [44]Yang S. Wang X. Contino G. Liesa M. Sahin E. Ying H. Bause A. Li Y. Stommel J.M. Dell’Antonio G. Pancreatic cancers require autophagy for tumor growth Genes Dev. 2011 25 717 729 10.1101/gad.2016111 21406549 PMC3070934 · DOI · Paper page
  41. [45]Endo S. Nakata K. Ohuchida K. Takesue S. Nakayama H. Abe T. Koikawa K. Okumura T. Sada M. Horioka K. Autophagy Is Required for Activation of Pancreatic Stellate Cells, Associated with Pancreatic Cancer Progression and Promotes Growth of Pancreatic Tumors in Mice Gastroenterology 2017 152 1492 1506.e24 10.1053/j.gastro.2017.01.010 28126348 · DOI
  42. [46]Frieboes H.B. Huang J.S. Yin W.C. McNally L.R. Chloroquine-mediated cell death in metastatic pancreatic adenocarcinoma through inhibition of autophagy JOP 2014 15 189 197 10.6092/1590-8577/1900 24618445 · DOI
  43. [47]Hashimoto D. Bläuer M. Hirota M. Ikonen N.H. Sand J. Laukkarinen J. Autophagy is needed for the growth of pancreatic adenocarcinoma and has a cytoprotective effect against anticancer drugs Eur. J. Cancer 2014 50 1382 1390 10.1016/j.ejca.2014.01.011 24503026 · DOI
  44. [48]Fu Z. Cheng X. Kuang J. Feng H. Chen L. Liang J. Shen X. Yuen S. Peng C. Shen B. CQ sensitizes human pancreatic cancer cells to gemcitabine through the lysosomal apoptotic pathway via reactive oxygen species Mol. Oncol. 2018 12 529 544 10.1002/1878-0261.12179 29453806 PMC5891043 · DOI
  45. [49]Bryant K.L. Stalnecker C.A. Zeitouni D. Klomp J.E. Peng S. Tikunov A.P. Gunda V. Pierobon M. Waters A.M. George S.D. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer Nat. Med. 2019 25 628 640 10.1038/s41591-019-0368-8 30833752 PMC6484853 · DOI · Paper page
  46. [50]Yamamoto K. Venida A. Yano J. Biancur D.E. Kakiuchi M. Gupta S. Sohn A.S.W. Mukhopadhyay S. Lin E.Y. Parker S.J. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I Nature 2020 581 100 105 10.1038/s41586-020-2229-5 32376951 PMC7296553 · DOI · Paper page
  47. [51]Balic A. Sørensen M.D. Trabulo S.M. Sainz B. Cioffi M. Vieira C.R. Miranda-Lorenzo I. Hidalgo M. Kleeff J. Erkan M. Chloroquine Targets Pancreatic Cancer Stem Cells via Inhibition of CXCR4 and Hedgehog Signaling Mol. Cancer Ther. 2014 13 1758 1771 10.1158/1535-7163.MCT-13-0948 24785258 · DOI
  48. [52]Jiang F. Xing H. Chen W. Du J. Ruan Y. Lin A. Zhou C. Itraconazole inhibits proliferation of pancreatic cancer cells through activation of Bak-1 J. Cell. Biochem. 2019 120 4333 4341 10.1002/jcb.27719 30260036 · DOI
  49. [53]Chen K. Cheng L. Qian W. Jiang Z. Sun L. Zhao Y. Zhou Y. Zhao L. Wang P. Duan W. Itraconazole inhibits invasion and migration of pancreatic cancer cells by suppressing TGF-β/SMAD2/3 signaling Oncol. Rep. 2018 39 1573 1582 10.3892/or.2018.6281 29484419 · DOI
  50. [54]Kim S. Toyokawa H. Yamao J. Satoi S. Yanagimoto H. Yamamoto T. Hirooka S. Yamaki S. Inoue K. Matsui Y. Antitumor Effect of Angiotensin II Type 1 Receptor Blocker Losartan for Orthotopic Rat Pancreatic Adenocarcinoma Pancreas 2014 43 886 890 10.1097/MPA.0000000000000125 24717824 · DOI
  51. [55]Li Y. Tang Y. Chen S. Liu Y. Wang S. Tian Y. Wang C. Teng Z. Lu G. Sequential therapy for pancreatic cancer by losartan- and gemcitabine-loaded magnetic mesoporous spheres RSC Adv. 2019 9 19690 19698 10.1039/C9RA02180A PMC9065328 35519380 · DOI
  52. [56]Chauhan V.P. Martin J.D. Liu H. Lacorre D.A. Jain S.R. Kozin S.V. Stylianopoulos T. Mousa A.S. Han X. Adstamongkonkul P. Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels Nat. Commun. 2013 4 2516 10.1038/ncomms3516 24084631 PMC3806395 · DOI · Paper page
  53. [58]Incio J. Liu H. Suboj P. Chin S.M. Chen I.X. Pinter M. Ng M.R. Nia H.T. Grahovac J. Kao S. Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy Cancer Discov. 2016 6 852 869 10.1158/2159-8290.CD-15-1177 27246539 PMC4972679 · DOI
  54. [59]Arnold S.A. Rivera L.B. Carbon J.G. Toombs J.E. Chang C.-L. Bradshaw A.D. Brekken R.A. Losartan Slows Pancreatic Tumor Progression and Extends Survival of SPARC-Null Mice by Abrogating Aberrant TGFβ Activation PLoS ONE 2012 7 e31384 10.1371/journal.pone.0031384 22348081 PMC3279359 · DOI
  55. [61]Kisfalvi K. Eibl G. Sinnett-Smith J. Rozengurt E. Metformin Disrupts Crosstalk between G Protein–Coupled Receptor and Insulin Receptor Signaling Systems and Inhibits Pancreatic Cancer Growth Cancer Res. 2009 69 6539 6545 10.1158/0008-5472.CAN-09-0418 19679549 PMC2753241 · DOI
  56. [62]Karnevi E. Said K. Andersson R. Rosendahl A.H. Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells BMC Cancer 2013 13 235 10.1186/1471-2407-13-235 23663483 PMC3661399 · DOI
  57. [63]Veschi S. Ronci M. Lanuti P. De Lellis L. Florio R. Bologna G. Scotti L. Carletti E. Brugnoli F. Di Bella M.C. Integrative proteomic and functional analyses provide novel insights into the action of the repurposed drug candidate nitroxoline in AsPC-1 cells Sci. Rep. 2020 10 2574 10.1038/s41598-020-59492-4 32054977 PMC7018951 · DOI
  58. [64]Ramachandran S. Srivastava S.K. Repurposing Pimavanserin, an Anti-Parkinson Drug for Pancreatic Cancer Therapy Mol. Ther. Oncolytics 2020 19 19 32 10.1016/j.omto.2020.08.019 33024816 PMC7527685 · DOI
  59. [65]Usugi E. Ishii K. Hirokawa Y. Kanayama K. Matsuda C. Uchida K. Shiraishi T. Watanabe M. Antifibrotic Agent Pirfenidone Suppresses Proliferation of Human Pancreatic Cancer Cells by Inducing G0/G1 Cell Cycle Arrest Pharmacology 2019 103 250 256 10.1159/000496831 30731453 · DOI
  60. [66]Kozono S. Ohuchida K. Eguchi D. Ikenaga N. Fujiwara K. Cui L. Mizumoto K. Tanaka M. Pirfenidone Inhibits Pancreatic Cancer Desmoplasia by Regulating Stellate Cells Cancer Res. 2013 73 2345 2356 10.1158/0008-5472.CAN-12-3180 23348422 · DOI
  61. [67]Suklabaidya S. Das B. Ali S.A. Jain S. Swaminathan S. Mohanty A.K. Panda S.K. Dash P. Chakraborty S. Batra S.K. Characterization and use of HapT1-derived homologous tumors as a preclinical model to evaluate therapeutic efficacy of drugs against pancreatic tumor desmoplasia Oncotarget 2016 7 41825 41842 10.18632/oncotarget.9729 27259232 PMC5173099 · DOI
  62. [68]Xavier C.P.R. Castro I. Caires H.R. Ferreira D. Cavadas B. Pereira L. Santos L.L. Oliveira M.J. Vasconcelos M.H. Chitinase 3-like-1 and fibronectin in the cargo of extracellular vesicles shed by human macrophages influence pancreatic cancer cellular response to gemcitabine Cancer Lett. 2021 501 210 223 10.1016/j.canlet.2020.11.013 33212158 · DOI
  63. [69]Ji T. Li S. Zhang Y. Lang J. Ding Y. Zhao X. Zhao R. Li Y. Shi J. Hao J. An MMP-2 Responsive Liposome Integrating Antifibrosis and Chemotherapeutic Drugs for Enhanced Drug Perfusion and Efficacy in Pancreatic Cancer ACS Appl. Mater. Interfaces 2016 8 3438 3445 10.1021/acsami.5b11619 26759926 · DOI
  64. [70]Ji T. Lang J. Wang J. Cai R. Zhang Y. Qi F. Zhang L. Zhao X. Wu W. Hao J. Designing Liposomes to Suppress Extracellular Matrix Expression to Enhance Drug Penetration and Pancreatic Tumor Therapy ACS Nano 2017 11 8668 8678 10.1021/acsnano.7b01026 28806504 · DOI
  65. [71]Gao F. Wu J. Niu S. Sun T. Li F. Bai Y. Jin L. Lin L. Shi Q. Zhu L.-M. Biodegradable, pH-Sensitive Hollow Mesoporous Organosilica Nanoparticle (HMON) with Controlled Release of Pirfenidone and Ultrasound-Target-Microbubble-Destruction (UTMD) for Pancreatic Cancer Treatment Theranostics 2019 9 6002 6018 10.7150/thno.36135 31534533 PMC6735371 · DOI
  66. [72]Renz B.W. Takahashi R. Tanaka T. Macchini M. Hayakawa Y. Dantes Z. Maurer H.C. Chen X. Jiang Z. Westphalen C.B. β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer Cancer Cell 2018 33 75 90.e7 10.1016/j.ccell.2017.11.007 29249692 PMC5760435 · DOI · Paper page
  67. [73]Zhang D. Ma Q. Shen S. Hu H. Inhibition of Pancreatic Cancer Cell Proliferation by Propranolol Occurs Through Apoptosis Induction Pancreas 2009 38 94 100 10.1097/MPA.0b013e318184f50c 19106745 · DOI
  68. [74]Zhang D. Ma Q.Y. Hu H.-T. Zhang M. β2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NF-κB and AP-1 Cancer Biol. Ther. 2010 10 19 29 10.4161/cbt.10.1.11944 20424515 · DOI
  69. [75]Partecke L.I. Speerforck S. Kading A. Seubert F. Kühn S. Lorenz E. Schwandke S. Sendler M. Keßler W. Trung D.N. Chronic stress increases experimental pancreatic cancer growth, reduces survival and can be antagonised by beta-adrenergic receptor blockade Pancreatology 2016 16 423 433 10.1016/j.pan.2016.03.005 27083074 · DOI
  70. [76]Li M. Xu H. Fear stress enhanced xenograft pancreatic tumor growth through activating epithelial-mesenchymal transition Pancreatology 2019 19 377 382 10.1016/j.pan.2019.01.002 30733163 · DOI
  71. [77]Al-Wadei H.A. Al-Wadei M.H. Schuller H.M. Prevention of pancreatic cancer by the beta-blocker propranolol Anticancer Drugs 2009 20 477 482 10.1097/CAD.0b013e32832bd1e3 19387337 PMC3366433 · DOI
  72. [78]Samaras P. Tusup M. Nguyen-Kim T.D.L. Seifert B. Bachmann H. von Moos R. Knuth A. Pascolo S. Phase I study of a chloroquine–gemcitabine combination in patients with metastatic or unresectable pancreatic cancer Cancer Chemother. Pharmacol. 2017 80 1005 1012 10.1007/s00280-017-3446-y 28980060 · DOI
  73. [81]Karasic T.B. O’Hara M.H. Loaiza-Bonilla A. Reiss K.A. Teitelbaum U.R. Borazanci E. De Jesus-Acosta A. Redlinger C. Burrell J.A. Laheru D.A. Effect of Gemcitabine and nab-Paclitaxel with or Without Hydroxychloroquine on Patients with Advanced Pancreatic Cancer JAMA Oncol. 2019 5 993 10.1001/jamaoncol.2019.0684 31120501 PMC6547080 · DOI
  74. [82]Brunner T.B. Geiger M. Grabenbauer G.G. Lang-Welzenbach M. Mantoni T.S. Cavallaro A. Sauer R. Hohenberger W. McKenna W.G. Phase I Trial of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir and Chemoradiation for Locally Advanced Pancreatic Cancer J. Clin. Oncol. 2008 26 2699 2706 10.1200/JCO.2007.15.2355 18509182 · DOI
  75. [83]Lin C. Verma V. Ly Q.P. Lazenby A. Sasson A. Schwarz J.K. Meza J.L. Are C. Li S. Wang S. Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma Radiother. Oncol. 2019 132 55 62 10.1016/j.radonc.2018.11.002 30825970 PMC6400311 · DOI
  76. [84]Wilson J.M. Fokas E. Dutton S.J. Patel N. Hawkins M.A. Eccles C. Chu K.-Y. Durrant L. Abraham A.G. Partridge M. ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer Radiother. Oncol. 2016 119 306 311 10.1016/j.radonc.2016.03.021 27117177 PMC4917892 · DOI
  77. [85]Lin C. Verma V. Lazenby A. Ly Q.P. Berim L.D. Schwarz J.K. Madiyalakan M. Nicodemus C.F. Hollingsworth M.A. Meza J.L. Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir for Locally Advanced Pancreatic Adenocarcinoma Am. J. Clin. Oncol. 2019 42 755 760 10.1097/COC.0000000000000599 31513018 PMC6768754 · DOI
  78. [86]Strauss V.Y. Shaw R. Virdee P.S. Hurt C.N. Ward E. Tranter B. Patel N. Bridgewater J. Parsons P. Radhakrishna G. Study protocol: A multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2) BMC Cancer 2019 19 121 10.1186/s12885-019-5307-z 30717707 PMC6360784 · DOI
  79. [87]Murphy J.E. Wo J.Y. Ryan D.P. Clark J.W. Jiang W. Yeap B.Y. Drapek L.C. Ly L. Baglini C.V. Blaszkowsky L.S. Total Neoadjuvant Therapy with FOLFIRINOX in Combination with Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer JAMA Oncol. 2019 5 1020 10.1001/jamaoncol.2019.0892 31145418 PMC6547247 · DOI
  80. [88]Braghiroli M.I. de Celis Ferrari A.C.R. Pfiffer T.E. Alex A.K. Nebuloni D. Carneiro A.S. Caparelli F. Senna L. Lobo J. Hoff P.M. Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas Ecancermedicalscience 2015 9 563 10.3332/ecancer.2015.563 26316884 PMC4544571 · DOI
  81. [89]Kordes S. Pollak M.N. Zwinderman A.H. Mathôt R.A. Weterman M.J. Beeker A. Punt C.J. Richel D.J. Wilmink J.W. Metformin in patients with advanced pancreatic cancer: A double-blind, randomised, placebo-controlled phase 2 trial Lancet Oncol. 2015 16 839 847 10.1016/S1470-2045(15)00027-3 26067687 · DOI
  82. [90]Reni M. Dugnani E. Cereda S. Belli C. Balzano G. Nicoletti R. Liberati D. Pasquale V. Scavini M. Maggiora P. (Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial Clin. Cancer Res. 2016 22 1076 1085 10.1158/1078-0432.CCR-15-1722 26459175 · DOI
  83. [92]Emery P. Suarez-Almazor M. Rheumatoid arthritis Clin. Evid. 2003 1349 1371 15366179
  84. [93]Varghese E. Büsselberg D. Auranofin, an Anti-Rheumatic Gold Compound, Modulates Apoptosis by Elevating the Intracellular Calcium Concentration ([Ca2+]i) in MCF-7 Breast Cancer Cells Cancers 2014 6 2243 2258 10.3390/cancers6042243 25383481 PMC4276964 · DOI
  85. [94]Roder C. Thomson M.J. Auranofin: Repurposing an Old Drug for a Golden New Age Drugs R D 2015 15 13 20 10.1007/s40268-015-0083-y 25698589 PMC4359176 · DOI
  86. [95]Li H. Hu J. Wu S. Wang L. Cao X. Zhang X. Dai B. Cao M. Shao R. Zhang R. Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells Oncotarget 2016 7 3548 3558 10.18632/oncotarget.6516 26657290 PMC4823126 · DOI
  87. [96]Cramer S.L. Saha A. Liu J. Tadi S. Tiziani S. Yan W. Triplett K. Lamb C. Alters S.E. Rowlinson S. Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth Nat. Med. 2017 23 120 127 10.1038/nm.4232 27869804 PMC5218918 · DOI
  88. [97]Jatoi A. Breitkopf C.R. Foster N.R. Block M.S. Grudem M. Hendrickson A.W. Carlson R.E. Barrette B. Karlin N. Fields A.P. A Mixed-Methods Feasibility Trial of Protein Kinase C Iota Inhibition with Auranofin in Asymptomatic Ovarian Cancer Patients Oncology 2015 88 208 213 10.1159/000369257 25502607 PMC4536897 · DOI
  89. [98]Li P. Snyder G.L. Vanover K.E. Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future Curr. Top. Med. Chem. 2016 16 3385 3403 10.2174/1568026616666160608084834 27291902 PMC5112764 · DOI
  90. [99]Hendouei N. Saghafi F. Shadfar F. Hosseinimehr S.J. Molecular mechanisms of anti-psychotic drugs for improvement of cancer treatment Eur. J. Pharmacol. 2019 856 172402 10.1016/j.ejphar.2019.05.031 31108054 · DOI
  91. [100]Xu S. Furukawa T. Kanai N. Sunamura M. Horii A. Abrogation of DUSP6 by hypermethylation in human pancreatic cancer J. Hum. Genet. 2005 50 159 167 10.1007/s10038-005-0235-y 15824892 · DOI
  92. [101]Owens D.M. Keyse S.M. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases Oncogene 2007 26 3203 3213 10.1038/sj.onc.1210412 17496916 · DOI · Paper page
  93. [103]Johnson B.E. Parker R. Tsai C.M. Baltz J. Miller M.J. Shoemaker R. Phelps R. Bastian A. Stocker J. Phares J. Phase I trial of dihydrolenperone in lung cancer patients: A novel compound within vitro activity against lung cancer Investig. New Drugs 1993 11 29 37 10.1007/BF00873907 8349433 · DOI
  94. [104]Vural G. Yardimci M. Kocak M. Yasar T.Ö. Kurt A. Harem I.S. Carradori S. Sciamanna I. Siles-Lucas M. Fabiani M. Efficacy of novel albendazole salt formulations against secondary cystic echinococcosis in experimentally infected mice Parasitology 2020 147 1425 1432 10.1017/S0031182020001225 32729453 PMC10317756 · DOI
  95. [105]Son D.-S. Lee E.-S. Adunyah S.E. The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs Immune Netw. 2020 20 e29 10.4110/in.2020.20.e29 32895616 PMC7458798 · DOI · Paper page
  96. [106]Florio R. Carradori S. Veschi S. Brocco D. Di Genni T. Cirilli R. Casulli A. Cama A. De Lellis L. Screening of Benzimidazole-Based Anthelmintics and Their Enantiomers as Repurposed Drug Candidates in Cancer Therapy Pharmaceuticals 2021 14 372 10.3390/ph14040372 33920661 PMC8072969 · DOI
  97. [107]Chen H. Weng Z. Xu C. Albendazole suppresses cell proliferation and migration and induces apoptosis in human pancreatic cancer cells Anticancer Drugs 2020 31 431 439 10.1097/CAD.0000000000000914 32044795 · DOI
  98. [108]Pourgholami M.H. Szwajcer M. Chin M. Liauw W. Seef J. Galettis P. Morris D.L. Links M. Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer Cancer Chemother. Pharmacol. 2010 65 597 605 10.1007/s00280-009-1157-8 19904538 · DOI · Paper page
  99. [109]Morris D.L. Jourdan J.-L. Pourgholami M.H. Pilot Study of Albendazole in Patients with Advanced Malignancy Oncology 2001 61 42 46 10.1159/000055351 11474247 · DOI · Paper page
  100. [110]Koppaka V. Thompson D.C. Chen Y. Ellermann M. Nicolaou K.C. Juvonen R.O. Petersen D. Deitrich R.A. Hurley T.D. Vasiliou V. Aldehyde Dehydrogenase Inhibitors: A Comprehensive Review of the Pharmacology, Mechanism of Action, Substrate Specificity, and Clinical Application Pharmacol. Rev. 2012 64 520 539 10.1124/pr.111.005538 22544865 PMC3400832 · DOI
  101. [111]Lu C. Li X. Ren Y. Zhang X. Disulfiram: A novel repurposed drug for cancer therapy Cancer Chemother. Pharmacol. 2021 87 159 172 10.1007/s00280-020-04216-8 33426580 · DOI
  102. [112]Rinkenbaugh A. Baldwin A. The NF-κB Pathway and Cancer Stem Cells Cells 2016 5 16 10.3390/cells5020016 27058560 PMC4931665 · DOI
  103. [113]Kelley K.C. Grossman K.F. Brittain-Blankenship M. Thorne K.M. Akerley W.L. Terrazas M.C. Kosak K.M. Boucher K.M. Buys S.S. McGregor K.A. A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker BMC Cancer 2021 21 510 10.1186/s12885-021-08242-4 33957901 PMC8103752 · DOI
  104. [114]Chopra I. Roberts M. Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance Microbiol. Mol. Biol. Rev. 2001 65 232 260 10.1128/MMBR.65.2.232-260.2001 11381101 PMC99026 · DOI · Paper page
  105. [115]Ali I. Alfarouk K.O. Reshkin S.J. Ibrahim M.E. Doxycycline as Potential Anti-cancer Agent Anticancer Agents Med. Chem. 2018 17 1617 1623 10.2174/1871520617666170213111951 28270076 · DOI
  106. [116]Moullan N. Mouchiroud L. Wang X. Ryu D. Williams E.G. Mottis A. Jovaisaite V. Frochaux M.V. Quiros P.M. Deplancke B. Tetracyclines Disturb Mitochondrial Function across Eukaryotic Models: A Call for Caution in Biomedical Research Cell Rep. 2015 10 1681 1691 10.1016/j.celrep.2015.02.034 25772356 PMC4565776 · DOI
  107. [117]Lamb R. Harrison H. Hulit J. Smith D.L. Lisanti M.P. Sotgia F. Mitochondria as new therapeutic targets for eradicating cancer stem cells: Quantitative proteomics and functional validation via MCT1/2 inhibition Oncotarget 2014 5 11029 11037 10.18632/oncotarget.2789 25415228 PMC4294326 · DOI
  108. [118]Huie M. Oettel K. Van Ummersen L. Kim K.M. Zhang Y. Staab M.J. Horvath D. Marnocha R. Douglas J. Drezen A. Phase II study of interferon-alpha and doxycycline for advanced renal cell carcinoma Investig. New Drugs 2006 24 255 260 10.1007/s10637-005-3903-z 16205854 · DOI
  109. [119]De Clercq E. Li G. Approved Antiviral Drugs over the Past 50 Years Clin. Microbiol. Rev. 2016 29 695 747 10.1128/CMR.00102-15 27281742 PMC4978613 · DOI
  110. [120]Chow W.A. Jiang C. Guan M. Anti-HIV drugs for cancer therapeutics: Back to the future? Lancet Oncol. 2009 10 61 71 10.1016/S1470-2045(08)70334-6 19111246 · DOI
  111. [121]Kaushik I. Ramachandran S. Prasad S. Srivastava S.K. Drug rechanneling: A novel paradigm for cancer treatment Semin. Cancer Biol. 2021 68 279 290 10.1016/j.semcancer.2020.03.011 32437876 PMC7786449 · DOI
  112. [122]Van den Berg-Wolf M. Hullsiek K.H. Peng G. Kozal M.J. Novak R.M. Chen L. Crane L.R. MacArthur R.D. Virologic, Immunologic, Clinical, Safety, and Resistance Outcomes from a Long-Term Comparison of Efavirenz-Based Versus Nevirapine-Based Antiretroviral Regimens as Initial Therapy in HIV-1—Infected Persons HIV Clin. Trials 2008 9 324 336 10.1310/hct0905-324 18977721 · DOI
  113. [123]Landriscina M. Fabiano A. Altamura S. Bagalà C. Piscazzi A. Cassano A. Spadafora C. Giorgino F. Barone C. Cignarelli M. Reverse Transcriptase Inhibitors Down-Regulate Cell Proliferation in Vitro and in Vivo and Restore Thyrotropin Signaling and Iodine Uptake in Human Thyroid Anaplastic Carcinoma J. Clin. Endocrinol. Metab. 2005 90 5663 5671 10.1210/jc.2005-0367 16030158 · DOI
  114. [124]Zhang R. Zhang F. Sun Z. Liu P. Zhang X. Ye Y. Cai B. Walsh M.J. Ren X. Hao X. LINE-1 Retrotransposition Promotes the Development and Progression of Lung Squamous Cell Carcinoma by Disrupting the Tumor-Suppressor Gene FGGY Cancer Res. 2019 79 4453 4465 10.1158/0008-5472.CAN-19-0076 31289132 · DOI
  115. [125]Kim I.-A. Bae S.-S. Fernandes A. Wu J. Muschel R.J. McKenna W.G. Birnbaum M.J. Bernhard E.J. Selective Inhibition of Ras, Phosphoinositide 3 Kinase, and Akt Isoforms Increases the Radiosensitivity of Human Carcinoma Cell Lines Cancer Res. 2005 65 7902 7910 10.1158/0008-5472.CAN-05-0513 16140961 · DOI
  116. [126]Brunner T.B. Cengel K.A. Hahn S.M. Wu J. Fraker D.L. McKenna W.G. Bernhard E.J. Pancreatic Cancer Cell Radiation Survival and Prenyltransferase Inhibition: The Role of K-Ras Cancer Res. 2005 65 8433 8441 10.1158/0008-5472.CAN-05-0158 16166322 · DOI
  117. [127]Gupta A.K. Cerniglia G.J. Mick R. McKenna W.G. Muschel R.J. HIV Protease Inhibitors Block Akt Signaling and Radiosensitize Tumor Cells Both In vitro and In vivo Cancer Res. 2005 65 8256 8265 10.1158/0008-5472.CAN-05-1220 16166302 · DOI
  118. [128]Rauschenbach L. Wieland A. Reinartz R. Kebir S. Till A. Oppong M.D. Dobersalske C. Ullrich V. Ahmad A. Jabbarli R. Drug repositioning of antiretroviral ritonavir for combinatorial therapy in glioblastoma Eur. J. Cancer 2020 140 130 139 10.1016/j.ejca.2020.09.017 33091717 · DOI
  119. [129]Ikezoe T. Hisatake Y. Takeuchi T. Ohtsuki Y. Yang Y. Said J.W. Taguchi H. Koeffler H.P. HIV-1 Protease Inhibitor, Ritonavir Cancer Res. 2004 64 7426 7431 10.1158/0008-5472.CAN-03-2677 15492266 · DOI
  120. [130]Isono M. Sato A. Asano T. Okubo K. Asano T. Delanzomib Interacts with Ritonavir Synergistically to Cause Endoplasmic Reticulum Stress in Renal Cancer Cells Anticancer Res. 2018 38 3493 3500 10.21873/anticanres.12620 29848702 · DOI
  121. [131]Blumenthal G.M. Gills J.J. Ballas M.S. Bernstein W.B. Komiya T. Dechowdhury R. Morrow B. Root H. Chun G. Helsabeck C. A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors Oncotarget 2014 5 8161 8172 10.18632/oncotarget.2415 25327558 PMC4226674 · DOI
  122. [132]Mukherjee S. Virdee P. Shaw R. Bridgewater J. Radhakrishna G. Falk S. Scott-Brown M. Strauss V.Y. Brooks C. Gillmore R. SCALOP-2: A multi-centre randomised trial of induction chemotherapy followed by capecitabine +/-nelfinavir with high or standard dose radiotherapy for locally advanced pancreatic cancer (LAPC): Results of stage 1 the non-randomised dose-finding component Ann. Oncol. 2018 29 viii243 10.1093/annonc/mdy282.103 · DOI
  123. [133]Nirk E.L. Reggiori F. Mauthe M. Hydroxychloroquine in rheumatic autoimmune disorders and beyond EMBO Mol. Med. 2020 12 e12476 10.15252/emmm.202012476 32715647 PMC7411564 · DOI
  124. [134]Verbaanderd C. Maes H. Schaaf M.B. Sukhatme V.P. Pantziarka P. Sukhatme V. Agostinis P. Bouche G. Repurposing Drugs in Oncology (ReDO)—chloroquine and hydroxychloroquine as anti-cancer agents Ecancermedicalscience 2017 11 781 10.3332/ecancer.2017.781 29225688 PMC5718030 · DOI
  125. [135]Renz B. D’Haese J. Werner J. Westphalen C. Ilmer M. Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs) Med. Sci. 2017 5 14 10.3390/medsci5020014 29099030 PMC5635789 · DOI
  126. [136]Mauthe M. Orhon I. Rocchi C. Zhou X. Luhr M. Hijlkema K.-J. Coppes R.P. Engedal N. Mari M. Reggiori F. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion Autophagy 2018 14 1435 1455 10.1080/15548627.2018.1474314 29940786 PMC6103682 · DOI · Paper page
  127. [137]Yun C. Lee S. The Roles of Autophagy in Cancer Int. J. Mol. Sci. 2018 19 3466 10.3390/ijms19113466 30400561 PMC6274804 · DOI · Paper page
  128. [138]Piffoux M. Eriau E. Cassier P.A. Autophagy as a therapeutic target in pancreatic cancer Br. J. Cancer 2021 124 333 344 10.1038/s41416-020-01039-5 32929194 PMC7852577 · DOI
  129. [139]Wolpin B.M. Rubinson D.A. Wang X. Chan J.A. Cleary J.M. Enzinger P.C. Fuchs C.S. McCleary N.J. Meyerhardt J.A. Ng K. Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma Oncologist 2014 19 637 638 10.1634/theoncologist.2014-0086 24821822 PMC4041680 · DOI
  130. [140]Bao P. Potter D. Eisenberg D.P. Lenzner D. Zeh H.J. Lee K.K.W. Hughes S.J. Sanders M.K. Young J.L. Moser A.J. Validation of a prediction rule to maximize curative (R0) resection of early-stage pancreatic adenocarcinoma HPB 2009 11 606 611 10.1111/j.1477-2574.2009.00110.x 20495714 PMC2785957 · DOI
  131. [141]Kinsey C.G. Camolotto S.A. Boespflug A.M. Guillen K.P. Foth M. Truong A. Schuman S.S. Shea J.E. Seipp M.T. Yap J.T. Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers Nat. Med. 2019 25 620 627 10.1038/s41591-019-0367-9 30833748 PMC6452642 · DOI · Paper page
  132. [142]De Beule K. Van Gestel J. Pharmacology of Itraconazole Drugs 2001 61 27 37 10.2165/00003495-200161001-00003 11219548 · DOI · Paper page
  133. [143]Pounds R. Leonard S. Dawson C. Kehoe S. Repurposing itraconazole for the treatment of cancer Oncol. Lett. 2017 14 2587 2597 10.3892/ol.2017.6569 28927025 PMC5588108 · DOI
  134. [144]Kim J. Tang J.Y. Gong R. Kim J. Lee J.J. Clemons K.V. Chong C.R. Chang K.S. Fereshteh M. Gardner D. Itraconazole, a Commonly Used Antifungal that Inhibits Hedgehog Pathway Activity and Cancer Growth Cancer Cell 2010 17 388 399 10.1016/j.ccr.2010.02.027 20385363 PMC4039177 · DOI · Paper page
  135. [145]Thayer S.P. di Magliano M.P. Heiser P.W. Nielsen C.M. Roberts D.J. Lauwers G.Y. Qi Y.P. Gysin S. Castillo C.F. Yajnik V. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis Nature 2003 425 851 856 10.1038/nature02009 14520413 PMC3688051 · DOI
  136. [146]Lee J.J. Perera R.M. Wang H. Wu D.-C. Liu X.S. Han S. Fitamant J. Jones P.D. Ghanta K.S. Kawano S. Stromal response to Hedgehog signaling restrains pancreatic cancer progression Proc. Natl. Acad. Sci. USA 2014 111 E3091 E3100 10.1073/pnas.1411679111 25024225 PMC4121834 · DOI · Paper page
  137. [148]Tsubamoto H. Sonoda T. Ikuta S. Tani S. Inoue K. Yamanaka N. Combination Chemotherapy with Itraconazole for Treating Metastatic Pancreatic Cancer in the Second-line or Additional Setting Anticancer Res. 2015 35 4191 4196 26124377
  138. [149]Rahma O.E. Duffy A. Liewehr D.J. Steinberg S.M. Greten T.F. Second-line treatment in advanced pancreatic cancer: A comprehensive analysis of published clinical trials Ann. Oncol. 2013 24 1972 1979 10.1093/annonc/mdt166 23670093 PMC3718508 · DOI
  139. [150]Simpson K.L. McClellan K.J. Losartan Drugs Aging 2000 16 227 250 10.2165/00002512-200016030-00006 10803861 · DOI
  140. [151]Leung P.S. Chappell M.C. A local pancreatic renin-angiotensin system: Endocrine and exocrine roles Int. J. Biochem. Cell Biol. 2003 35 838 846 10.1016/S1357-2725(02)00179-6 12676170 · DOI
  141. [152]George A.J. Thomas W.G. Hannan R.D. The renin–angiotensin system and cancer: Old dog, new tricks Nat. Rev. Cancer 2010 10 745 759 10.1038/nrc2945 20966920 · DOI
  142. [153]Tamarat R. Silvestre J.-S. Durie M. Levy B.I. Angiotensin II angiogenic effect in vivo involves vascular endothelial growth factor- and inflammation-related pathways Lab. Investig. 2002 82 747 756 10.1097/01.LAB.0000017372.76297.EB 12065685 · DOI
  143. [154]Arafat H.A. Gong Q. Chipitsyna G. Rizvi A. Saa C.T. Yeo C.J. Antihypertensives as Novel Antineoplastics: Angiotensin-I-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Blockers in Pancreatic Ductal Adenocarcinoma J. Am. Coll. Surg. 2007 204 996 1005 10.1016/j.jamcollsurg.2007.01.067 17481528 · DOI
  144. [155]Hauge A. Rofstad E.K. Antifibrotic therapy to normalize the tumor microenvironment J. Transl. Med. 2020 18 207 10.1186/s12967-020-02376-y 32434573 PMC7240990 · DOI
  145. [156]Khoshghamat N. Jafari N. Toloue-pouya V. Azami S. Mirnourbakhsh S.H. Khazaei M. Ferns G.A. Rajabian M. Avan A. The therapeutic potential of renin-angiotensin system inhibitors in the treatment of pancreatic cancer Life Sci. 2021 270 119118 10.1016/j.lfs.2021.119118 33548284 · DOI
  146. [157]Yang J. Yang X. Gao L. Zhang J. Yi C. Huang Y. The role of the renin-angiotensin system inhibitors in malignancy: A review Am. J. Cancer Res. 2021 11 884 897 33791161 PMC7994166
  147. [158]Liu W.-B. Effects of angiotensin II receptor antagonist, Losartan on the apoptosis, proliferation and migration of the human pancreatic stellate cells World J. Gastroenterol. 2005 11 6489 10.3748/wjg.v11.i41.6489 16425421 PMC4355791 · DOI
  148. [159]Özdemir B.C. Pentcheva-Hoang T. Carstens J.L. Zheng X. Wu C.-C. Simpson T.R. Laklai H. Sugimoto H. Kahlert C. Novitskiy S.V. Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival Cancer Cell 2014 25 719 734 10.1016/j.ccr.2014.04.005 24856586 PMC4180632 · DOI · Paper page
  149. [162]El-Mir M.-Y. Nogueira V. Fontaine E. Avéret N. Rigoulet M. Leverve X. Dimethylbiguanide Inhibits Cell Respiration via an Indirect Effect Targeted on the Respiratory Chain Complex I J. Biol. Chem. 2000 275 223 228 10.1074/jbc.275.1.223 10617608 · DOI · Paper page
  150. [163]Zhou G. Myers R. Li Y. Chen Y. Shen X. Fenyk-Melody J. Wu M. Ventre J. Doebber T. Fujii N. Role of AMP-activated protein kinase in mechanism of metformin action J. Clin. Investig. 2001 108 1167 1174 10.1172/JCI13505 11602624 PMC209533 · DOI · Paper page
  151. [164]Shaw R.J. Lamia K.A. Vasquez D. Koo S.-H. Bardeesy N. Depinho R.A. Montminy M. Cantley L.C. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin Science 2005 310 1642 1646 10.1126/science.1120781 16308421 PMC3074427 · DOI · Paper page
  152. [165]Hardie D.G. Ross F.A. Hawley S.A. AMPK: A nutrient and energy sensor that maintains energy homeostasis Nat. Rev. Mol. Cell Biol. 2012 13 251 262 10.1038/nrm3311 22436748 PMC5726489 · DOI · Paper page
  153. [166]Foretz M. Hébrard S. Leclerc J. Zarrinpashneh E. Soty M. Mithieux G. Sakamoto K. Andreelli F. Viollet B. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state J. Clin. Investig. 2010 120 2355 2369 10.1172/JCI40671 20577053 PMC2898585 · DOI · Paper page
  154. [167]Pollak M. Insulin and insulin-like growth factor signalling in neoplasia Nat. Rev. Cancer 2008 8 915 928 10.1038/nrc2536 19029956 · DOI · Paper page
  155. [168]Ray L.B. Sturgill T.W. Insulin-stimulated microtubule associated protein kinase is detectable by analytical gel chromatography as a 35-kDa protein in myocytes, adipocytes, and hepatocytes Arch. Biochem. Biophys. 1988 262 307 313 10.1016/0003-9861(88)90193-2 3281589 · DOI
  156. [169]Lipner M.B. Marayati R. Deng Y. Wang X. Raftery L. O’Neil B.H. Yeh J.J. Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts PLoS ONE 2016 11 e0147113 10.1371/journal.pone.0147113 26760500 PMC4711922 · DOI
  157. [170]Eikawa S. Nishida M. Mizukami S. Yamazaki C. Nakayama E. Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin Proc. Natl. Acad. Sci. USA 2015 112 1809 1814 10.1073/pnas.1417636112 25624476 PMC4330733 · DOI
  158. [171]Tanaka R. Tomosugi M. Horinaka M. Sowa Y. Sakai T. Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer Cells PLoS ONE 2015 10 e0125779 10.1371/journal.pone.0125779 25955843 PMC4425682 · DOI
  159. [172]Cha J.-H. Yang W.-H. Xia W. Wei Y. Chan L.-C. Lim S.-O. Li C.-W. Kim T. Chang S.-S. Lee H.-H. Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1 Mol. Cell 2018 71 606 620.e7 10.1016/j.molcel.2018.07.030 30118680 PMC6786495 · DOI
  160. [173]Permert J. Adrian T.E. Jacobsson P. Jorfelt L. Fruin A.B. Larsson J. Is profound peripheral insulin resistance in patients with pancreatic cancer caused by a tumor-associated factor? Am. J. Surg. 1993 165 61 67 10.1016/S0002-9610(05)80405-2 8380314 · DOI
  161. [174]Currie C.J. Poole C.D. Jenkins-Jones S. Gale E.A.M. Johnson J.A. Morgan C.L. Mortality after Incident Cancer in People with and without Type 2 Diabetes: Impact of metformin on survival Diabetes Care 2012 35 299 304 10.2337/dc11-1313 22266734 PMC3263862 · DOI
  162. [175]Sadeghi N. Abbruzzese J.L. Yeung S.-C.J. Hassan M. Li D. Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer Clin. Cancer Res. 2012 18 2905 2912 10.1158/1078-0432.CCR-11-2994 22465831 PMC3381457 · DOI
  163. [176]Hwang A.L. Haynes K. Hwang W.-T. Yang Y.-X. Metformin and Survival in Pancreatic Cancer Pancreas 2013 42 1054 1059 10.1097/MPA.0b013e3182965a3c 24051965 PMC3779343 · DOI
  164. [177]Cerullo M. Gani F. Chen S.Y. Canner J. Pawlik T.M. Metformin Use Is Associated with Improved Survival in Patients Undergoing Resection for Pancreatic Cancer J. Gastrointest. Surg. 2016 20 1572 1580 10.1007/s11605-016-3173-4 27255657 · DOI
  165. [178]Chaiteerakij R. Petersen G.M. Bamlet W.R. Chaffee K.G. Zhen D.B. Burch P.A. Leof E.R. Roberts L.R. Oberg A.L. Metformin Use and Survival of Patients With Pancreatic Cancer: A Cautionary Lesson J. Clin. Oncol. 2016 34 1898 1904 10.1200/JCO.2015.63.3511 27069086 PMC4966342 · DOI
  166. [179]Beg M.S. Gupta A. Sher D. Ali S. Khan S. Gao A. Stewart T. Ahn C. Berry J. Mortensen E.M. Impact of Concurrent Medication Use on Pancreatic Cancer Survival—SEER-Medicare Analysis Am. J. Clin. Oncol. 2018 41 766 771 10.1097/COC.0000000000000359 28079594 PMC5503814 · DOI
  167. [180]Frouws M.A. Mulder B.G.S. Bastiaannet E. Zanders M.M.J. van Herk-Sukel M.P.P. de Leede E.M. Bonsing B.A. Mieog J.S.D. Van de Velde C.J.H. Liefers G.-J. No association between metformin use and survival in patients with pancreatic cancer Medicine 2017 96 e6229 10.1097/MD.0000000000006229 28272215 PMC5348163 · DOI
  168. [181]Cho J. Scragg R. Pandol S.J. Goodarzi M.O. Petrov M.S. Antidiabetic Medications and Mortality Risk in Individuals With Pancreatic Cancer–Related Diabetes and Postpancreatitis Diabetes: A Nationwide Cohort Study Diabetes Care 2019 42 1675 1683 10.2337/dc19-0145 31227582 PMC6702602 · DOI
  169. [182]Toriola A.T. Luo S. Thomas T.S. Drake B.F. Chang S.-H. Sanfilippo K.M. Carson K.R. Metformin Use and Pancreatic Cancer Survival among Non-Hispanic White and African American U.S. Veterans with Diabetes Mellitus Cancer Epidemiol. Biomark. Prev. 2020 29 169 175 10.1158/1055-9965.EPI-19-0781 31685560 PMC9448292 · DOI
  170. [183]Li X. Li T. Liu Z. Gou S. Wang C. The effect of metformin on survival of patients with pancreatic cancer: A meta-analysis Sci. Rep. 2017 7 5825 10.1038/s41598-017-06207-x 28724893 PMC5517652 · DOI
  171. [184]Zhou P.-T. Li B. Liu F.-R. Zhang M.-C. Wang Q. Li Y.-Y. Xu C. Liu Y.-H. Yao Y. Li D. Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: A systematic review and meta-analysis Oncotarget 2017 8 25242 25250 10.18632/oncotarget.15692 28445955 PMC5421925 · DOI
  172. [185]Jian-Yu E. Graber J.M. Lu S.-E. Lin Y. Lu-Yao G. Tan X.-L. Effect of Metformin and Statin Use on Survival in Pancreatic Cancer Patients: A Systematic Literature Review and Meta-analysis Curr. Med. Chem. 2018 25 2595 2607 10.2174/0929867324666170412145232 28403788 PMC5638687 · DOI
  173. [186]Morgillo F. Sasso F.C. Della Corte C.M. Vitagliano D. D’Aiuto E. Troiani T. Martinelli E. De Vita F. Orditura M. De Palma R. Synergistic Effects of Metformin Treatment in Combination with Gefitinib, a Selective EGFR Tyrosine Kinase Inhibitor, in LKB1 Wild-type NSCLC Cell Lines Clin. Cancer Res. 2013 19 3508 3519 10.1158/1078-0432.CCR-12-2777 23695170 · DOI
  174. [187]Lau Y.-K.I. Du X. Rayannavar V. Hopkins B. Shaw J. Bessler E. Thomas T. Pires M.M. Keniry M. Parsons R.E. Metformin and erlotinib synergize to inhibit basal breast cancer Oncotarget 2014 5 10503 10517 10.18632/oncotarget.2391 25361177 PMC4279389 · DOI
  175. [188]Cheng G. Lanza-Jacoby S. Metformin decreases growth of pancreatic cancer cells by decreasing reactive oxygen species: Role of NOX4 Biochem. Biophys. Res. Commun. 2015 465 41 46 10.1016/j.bbrc.2015.07.118 26225747 · DOI
  176. [189]Broadhurst P.J. Hart A.R. Metformin as an Adjunctive Therapy for Pancreatic Cancer: A Review of the Literature on Its Potential Therapeutic Use Dig. Dis. Sci. 2018 63 2840 2852 10.1007/s10620-018-5233-y 30159732 · DOI
  177. [190]Suissa S. Azoulay L. Metformin and the Risk of Cancer: Time-related biases in observational studies Diabetes Care 2012 35 2665 2673 10.2337/dc12-0788 23173135 PMC3507580 · DOI
  178. [191]Dekkers O.M. Groenwold R.H.H. When observational studies can give wrong answers: The potential of immortal time bias Eur. J. Endocrinol. 2021 184 E1 E4 10.1530/EJE-20-1124 33112276 · DOI
  179. [192]Dong Y.-W. Shi Y.-Q. He L.-W. Cui X.-Y. Su P.-Z. Effects of metformin on survival outcomes of pancreatic cancer: A meta-analysis Oncotarget 2017 8 55478 55488 10.18632/oncotarget.18233 28903435 PMC5589674 · DOI
  180. [193]Shi Y.-Q. Zhou X.-C. Du P. Yin M.-Y. Xu L. Chen W.-J. Xu C.-F. Relationships are between metformin use and survival in pancreatic cancer patients concurrent with diabetes Medicine 2020 99 e21687 10.1097/MD.0000000000021687 32925714 PMC7489714 · DOI · Paper page
  181. [194]Armando R. Gomez D.M. Gomez D. New drugs are not enough-drug repositioning in oncology: An update Int. J. Oncol. 2020 56 651 684 10.3892/ijo.2020.4966 32124955 PMC7010222 · DOI · Paper page
  182. [195]Kos J. Mitrović A. Nitroxoline: Repurposing its antimicrobial to antitumor application Acta Biochim. Pol. 2019 66 521 531 10.18388/abp.2019_2904 31834689 · DOI
  183. [196]Zhang Q. Wang S. Yang D. Pan K. Li L. Yuan S. Preclinical pharmacodynamic evaluation of antibiotic nitroxoline for anticancer drug repurposing Oncol. Lett. 2016 11 3265 3272 10.3892/ol.2016.4380 27123101 PMC4841112 · DOI
  184. [197]Shim J.S. Matsui Y. Bhat S. Nacev B.A. Xu J. Bhang H.C. Dhara S. Han K.C. Chong C.R. Pomper M.G. Effect of Nitroxoline on Angiogenesis and Growth of Human Bladder Cancer J. Natl. Cancer Inst. 2010 102 1855 1873 10.1093/jnci/djq457 21088277 PMC3001967 · DOI
  185. [198]Veschi S. Carradori S. De Lellis L. Florio R. Brocco D. Secci D. Guglielmi P. Spano M. Sobolev A.P. Cama A. Synthesis and evaluation of a large library of nitroxoline derivatives as pancreatic cancer antiproliferative agents J. Enzym. Inhib. Med. Chem. 2020 35 1331 1344 10.1080/14756366.2020.1780228 PMC7470072 32588672 · DOI
  186. [199]Dashtipour K. Gupta F. Hauser R.A. Karunapuzha C.A. Morgan J.C. Pimavanserin Treatment for Parkinson’s Disease Psychosis in Clinical Practice Parkinsons. Dis. 2021 2021 2603641 10.1155/2021/2603641 33489083 PMC7801085 · DOI
  187. [200]Hoxhaj G. Manning B.D. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism Nat. Rev. Cancer 2020 20 74 88 10.1038/s41568-019-0216-7 31686003 PMC7314312 · DOI · Paper page
  188. [201]Maréchal R. Bachet J.-B. Calomme A. Demetter P. Delpero J.R. Svrcek M. Cros J. Bardier-Dupas A. Puleo F. Monges G. Sonic Hedgehog and Gli1 Expression Predict Outcome in Resected Pancreatic Adenocarcinoma Clin. Cancer Res. 2015 21 1215 1224 10.1158/1078-0432.CCR-14-0667 25552484 · DOI
  189. [202]Azuma A. Pirfenidone treatment of idiopathic pulmonary fibrosis Ther. Adv. Respir. Dis. 2012 6 107 114 10.1177/1753465812436663 22333982 · DOI
  190. [203]Iyer S.N. Gurujeyalakshmi G. Giri S.N. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis J. Pharmacol. Exp. Ther. 1999 291 367 373 10490926
  191. [205]García L. Hernández I. Sandoval A. Salazar A. Garcia J. Vera J. Grijalva G. Muriel P. Margolin S. Armendariz-Borunda J. Pirfenidone effectively reverses experimental liver fibrosis J. Hepatol. 2002 37 797 805 10.1016/S0168-8278(02)00272-6 12445421 · DOI
  192. [206]Marwitz S. Turkowski K. Nitschkowski D. Weigert A. Brandenburg J. Reiling N. Thomas M. Reck M. Drömann D. Seeger W. The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC Front. Oncol. 2020 9 1550 10.3389/fonc.2019.01550 32039023 PMC6985561 · DOI
  193. [207]Merika E.E. Syrigos K.N. Saif M.W. Desmoplasia in Pancreatic Cancer. Can We Fight It? Gastroenterol. Res. Pract. 2012 2012 781765 10.1155/2012/781765 23125850 PMC3485537 · DOI
  194. [208]Nallanthighal S. Heiserman J.P. Cheon D.-J. The Role of the Extracellular Matrix in Cancer Stemness Front. Cell Dev. Biol. 2019 7 86 10.3389/fcell.2019.00086 31334229 PMC6624409 · DOI · Paper page
  195. [209]De Lellis L. Florio R. Di Bella M.C. Brocco D. Guidotti F. Tinari N. Grassadonia A. Lattanzio R. Cama A. Veschi S. Exosomes as Pleiotropic Players in Pancreatic Cancer Biomedicines 2021 9 275 10.3390/biomedicines9030275 33803470 PMC8002012 · DOI
  196. [210]Babovic-Vuksanovic D. Ballman K. Michels V. McGrann P. Lindor N. King B. Camp J. Micic V. Babovic N. Carrero X. Phase II trial of pirfenidone in adults with neurofibromatosis type 1 Neurology 2006 67 1860 1862 10.1212/01.wnl.0000243231.12248.67 17035676 · DOI
  197. [211]Widemann B.C. Babovic-Vuksanovic D. Dombi E. Wolters P.L. Goldman S. Martin S. Goodwin A. Goodspeed W. Kieran M.W. Cohen B. Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas Pediatr. Blood Cancer 2014 61 1598 1602 10.1002/pbc.25041 24753394 PMC7681788 · DOI
  198. [213]Qiao G. Chen M. Bucsek M.J. Repasky E.A. Hylander B.L. Adrenergic Signaling: A Targetable Checkpoint Limiting Development of the Antitumor Immune Response Front. Immunol. 2018 9 164 10.3389/fimmu.2018.00164 29479349 PMC5812031 · DOI
  199. [214]Forget P. Aguirre J.A. Bencic I. Borgeat A. Cama A. Condron C. Eintrei C. Eroles P. Gupta A. Hales T.G. How Anesthetic, Analgesic and Other Non-Surgical Techniques During Cancer Surgery Might Affect Postoperative Oncologic Outcomes: A Summary of Current State of Evidence Cancers 2019 11 592 10.3390/cancers11050592 PMC6563034 31035321 · DOI
  200. [215]Liang D. Shi S. Xu J. Zhang B. Qin Y. Ji S. Xu W. Liu J. Liu L. Liu C. New insights into perineural invasion of pancreatic cancer: More than pain Biochim. Biophys. Acta Rev. Cancer 2016 1865 111 122 10.1016/j.bbcan.2016.01.002 26794395 · DOI

200 of 207 shown

Cited by

Sorted by citations

Authors
De Lellis, L., Veschi, S., Tinari, N., Mokini, Z., Carradori, S., Brocco, D., Florio, R., Grassadonia, A., & Cama, A.
Affiliations
  • Department of Pharmacy, G. d’Annunzio University of Chieti-Pescara, 66100 Chieti, Italy
  • University of Chieti-Pescara (IT)
  • European Society of Anaesthesiology (BE)
Corresponding author
Cama, Alessandro
ORCID
Venue
Cancers
Publisher
MDPI AG
Published
2021-08-05
Volume
13
Issue
16
Pages
3946
ISSN
2072-6694 (ISSN-L)
DOI
10.3390/cancers13163946
PMC
PMC8394389
OpenAlex
W3188296940
Cited by
40
References
18
Citations by year
2026: 6 · 2025: 12 · 2024: 7 · 2023: 7 · 2022: 8
FWCI
0.67
Type
journal article
Language
en
Open access
Licence
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Ministry of Education, University and Research (MIUR), Progetti di Ricerca di Interesse Nazionale (PRIN) (2017EKMFTN_005)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
drug repurposing, pancreatic cancer, FDA-approved drugs, mechanism of action, molecular targets, bioinformatics analysis, immunomodulation, combination therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review